SARS-CoV-2 对单克隆抗体和小分子药物的耐药性。
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.
机构信息
Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
出版信息
Cell Chem Biol. 2024 Apr 18;31(4):632-657. doi: 10.1016/j.chembiol.2024.03.008.
Over four years have passed since the beginning of the COVID-19 pandemic. The scientific response has been rapid and effective, with many therapeutic monoclonal antibodies and small molecules developed for clinical use. However, given the ability for viruses to become resistant to antivirals, it is perhaps no surprise that the field has identified resistance to nearly all of these compounds. Here, we provide a comprehensive review of the resistance profile for each of these therapeutics. We hope that this resource provides an atlas for mutations to be aware of for each agent, particularly as a springboard for considerations for the next generation of antivirals. Finally, we discuss the outlook and thoughts for moving forward in how we continue to manage this, and the next, pandemic.
自 COVID-19 大流行开始以来，已经过去了四年。科学应对迅速而有效，已经开发出许多用于临床应用的治疗性单克隆抗体和小分子药物。然而，鉴于病毒对抗病毒药物产生耐药性的能力，几乎所有这些化合物都出现耐药性，这也许并不奇怪。在这里，我们全面回顾了这些治疗药物的耐药情况。我们希望这个资源为每个药物的突变提供一个图谱，特别是作为下一代抗病毒药物考虑的起点。最后，我们讨论了展望和思路，以继续管理这种情况，以及下一次大流行。
Zotero 插件